KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Long-Term Debt Issuances (2018 - 2022)

Gsk has reported Long-Term Debt Issuances over the past 11 years, most recently at $653.5 million for Q1 2022.

  • For Q1 2022, Long-Term Debt Issuances rose 176.19% year-over-year to $653.5 million; the TTM value through Mar 2022 reached $4.1 billion, up 2061.05%, while the annual FY2025 figure was $2.6 billion, 90.79% up from the prior year.
  • Long-Term Debt Issuances for Q1 2022 was $653.5 million at Gsk, up from -$1.5 billion in the prior quarter.
  • Over five years, Long-Term Debt Issuances peaked at $5.9 billion in Q4 2020 and troughed at -$10.9 billion in Q4 2018.
  • A 5-year average of -$2.1 billion and a median of -$1.7 billion in 2021 define the central range for Long-Term Debt Issuances.
  • Biggest five-year swings in Long-Term Debt Issuances: soared 298.81% in 2020 and later tumbled 126.26% in 2021.
  • Year by year, Long-Term Debt Issuances stood at -$10.9 billion in 2018, then soared by 72.89% to -$2.9 billion in 2019, then soared by 298.81% to $5.9 billion in 2020, then tumbled by 126.26% to -$1.5 billion in 2021, then surged by 142.49% to $653.5 million in 2022.
  • Business Quant data shows Long-Term Debt Issuances for GSK at $653.5 million in Q1 2022, -$1.5 billion in Q4 2021, and -$857.7 million in Q1 2021.